Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

Anthera Ph Form 4	armaceuticals Inc										
April 29, 20	016										
FORM	M 4 UNITED	STATES	SECU	DITIES /	ND FY	CHANCE	COMMISSION		APPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									3235-0287		
Check t if no los subject		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF							January 31, 2005 average		
Section Form 4 Form 5	revent to (SECURITIES					burden ho response	urs per			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	e Responses)										
1. Name and Address of Reporting Person <u>*</u> Thompson David E.			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
			Anthera Pharmaceuticals Inc [ANTH]				(Check all applicable)				
(Last) (First) (Middle)			3. Date of Earliest Transaction				Director 10% Owner Officer (give title Other (specify				
25801 INDUSTRIAL BLVD SUITE B			(Month/Day/Year) 04/27/2016				below)	below)			
	4. If Amendment, Date Original Filed(Month/Day/Year)			al	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person						
HAYWAR	RD, CA 94545						Form filed by Person	More than One R	Reporting		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	e Securities A	cquired, Disposed o	of, or Beneficia	ally Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or l of (D) 4 and 5) (A) or	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	eport on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly o	or indirectly.				
					Perso infor requi	ons who res nation cont red to respo ays a curre	spond to the colle- tained in this form ond unless the for ntly valid OMB co	are not m	SEC 1474 (9-02)		
	Tab					sposed of, or convertible s	Beneficially Owned securities)	l			
		saction Date /Day/Year)			4. Transact	5. Number tiorDerivative			7. Title and Amount of 8 Underlying Securities I		

Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)		S (
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	3
Stock Option (right to buy)	\$ 3.8	04/27/2016		А	41,379		<u>(1)</u>	04/27/2026	Common Stock	41,379 (1)	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Thompson David E. 25801 INDUSTRIAL BLVD SUITE B HAYWARD, CA 94545						
Signatures						

/s/ May Liu by power of 04/29/2016 attorney

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This non-statutory stock option vests and becomes exercisable in 12 equal monthly installments from the vesting commencement date of April 27, 2016 and will be fully exercisable on April 27, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.